1. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. Issue 11 (November 2022) Authors: Mallory, Raburn M; Formica, Neil; Pfeiffer, Susan; Wilkinson, Bethanie; Marcheschi, Alex; Albert, Gary; McFall, Heather; Robinson, Michelle; Plested, Joyce S; Zhu, Mingzhu; Cloney-Clark, Shane; Zhou, Bin; Chau, Gordon; Robertson, Andreana; Maciejewski, Sonia; Hammond, Holly L; Baracco, Lauren; Lo... Journal: Lancet infectious diseases Issue: Volume 22:Issue 11(2022) Page Start: 1565 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗